Shuttle Pharmaceuticals Financials - Benzinga

Shuttle Pharmaceuticals Holdings Inc

SHPHNASDAQ

Trade with Public

Trade with Public

$4.09

0.5013.93%

À la clôture: Sep 23, 5:00 PM EST

$4.00

0.4111.42%

Pré-ouverture: 6:13 AM EST

Résultats: Les résultats Q2 2026 ont été publiés le jeu. sept. 24th, pendant les heures de marché

Aperçu Actualités Prévisions de résultats ÉvénementsDonnées financièresSentiment Actionnariat Comparer Rapport sur les stocks

Shuttle Pharmaceuticals Financials

Shuttle Pharmaceuticals (SHPH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Shuttle Pharmaceuticals Q2 EPS $(3.10) Up From $(32.90) YoY

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(3.10) per share. This is a 90.58 percent increase over losses of $(32.90) per share from the same period last year.

Benzinga Newsdesk

PRO
Shuttle Pharmaceuticals Q1 EPS $(0.43) Up From $(7.60) YoY

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.43) per share. This is a 94.34 percent increase over losses of $(7.60) per share from the same period last year.

Benzinga Newsdesk

PRO
Shuttle Pharmaceuticals Q3 EPS $(1.05) Up From $(39.75) YoY

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(1.05) per share. This is a 97.36 percent increase over losses of $(39.75) per share from the same period last year.

Benzinga Newsdesk

PRO
Shuttle Pharmaceuticals Q2 EPS $(3.29) Up From $(24.12) YoY

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(3.29) per share. This is a 86.36 percent increase over losses of $(24.12) per share from the same period last year.

Benzinga Newsdesk

PRO
Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY

Benzinga Newsdesk

PRO
Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(1.59) per share. This is a 74.73 percent decrease over losses of $(0.91) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved